Vertex Pharmaceuticals Incorporated
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
Phase 2b Open-label Study of Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 45
- Registration Number
- NCT06794996
- Locations
- ๐บ๐ธ
Foundation for Sickle Cell Disease Research, LLC, Hollywood, Florida, United States
๐บ๐ธSouth Florida Research Institute, Lauderdale Lakes, Florida, United States
๐บ๐ธCTR Oakwater, LLC, Orlando, Florida, United States
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 400
- Registration Number
- NCT06747572
- Locations
- ๐บ๐ธ
General Clinical Research Center, University of Maryland Baltimore, Baltimore, Maryland, United States
๐จ๐ฆMcGill University Health Centre, Glen Site, Montreal, Canada
๐บ๐ธAlabama Kidney Research, Alabaster, Alabama, United States
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 300
- Registration Number
- NCT06696443
- Locations
- ๐บ๐ธ
Pinnacle Research Group, LLC, Anniston, Alabama, United States
๐บ๐ธAMR Daphne, AL, Daphne, Alabama, United States
๐บ๐ธScottsdale Clinical Trials, Scottsdale, Arizona, United States
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- Drug: Placebo (matched to SUZ)Drug: Placebo (matched to Pregabalin)
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 1100
- Registration Number
- NCT06628908
- Locations
- ๐บ๐ธ
Pinnacle Research Group, LLC, Anniston, Alabama, United States
๐บ๐ธSynexus Clinical Research US - Birmingham, Birmingham, Alabama, United States
๐บ๐ธAMR Daphne, AL, Daphne, Alabama, United States
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 300
- Registration Number
- NCT06619860
- Locations
- ๐ซ๐ท
Centre Hospitalier Universitaire de Clermont Ferrand, Clermont Ferrand, France
๐ซ๐ทHรดpital Cochin - Centre d'Evaluation et de Traitement de la Douleur (CETD), Paris, France
๐ซ๐ทCentre Hospitalier Universitaire (CHU) de Saint-Etienne - Hopital Nord, St Priest en Jarez, France
A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy
- Conditions
- Acute Pain
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 367
- Registration Number
- NCT06619847
- Locations
- ๐บ๐ธ
Shoals Medical Trials Inc., Sheffield, Alabama, United States
๐บ๐ธArizona Research Center, Phoenix, Arizona, United States
๐บ๐ธWoodland International Research Group, Little Rock, Arkansas, United States
A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 40
- Registration Number
- NCT06615570
- Locations
- ๐บ๐ธ
ICON Salt Lake City, Salt Lake City, Utah, United States
Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment
- Conditions
- Focal Segmental Glomerulosclerosis (FSGS)
- Interventions
- Drug: IXP
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 36
- Registration Number
- NCT06529796
- Locations
- ๐บ๐ธ
Division of Clinical Pharmacology, University of Miami, Miami, Florida, United States
๐บ๐ธGCP Research, Saint Petersburg, Florida, United States
๐บ๐ธTexas Liver Institute, San Antonio, Texas, United States
Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 31
- Registration Number
- NCT06523595
- Locations
- ๐บ๐ธ
ICON Salt Lake City, Salt Lake City, Utah, United States
A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT06508762
- Locations
- ๐บ๐ธ
ICON Salt Lake City, Salt Lake City, Utah, United States